These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 4825783)

  • 1. In vitro demonstration of complement-dependent cytotoxic antibodies to Moloney sarcoma cells.
    Tamerius JD; Hellström I
    J Immunol; 1974 Jun; 112(6):1987-96. PubMed ID: 4825783
    [No Abstract]   [Full Text] [Related]  

  • 2. Protective effect of immune sera against transplantable Moloney virus-induced sarcoma and lymphoma.
    Pearson GR; Redmon LW; Bass LR
    Cancer Res; 1973 Jan; 33(1):171-8. PubMed ID: 4734119
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s).
    Lamon EW; Skurzak HM; Andersson B; Whitten HD; Klein E
    J Immunol; 1975 Apr; 114(4):1171-6. PubMed ID: 1117138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immune response to primary Moloney sarcoma virus tumors in BALB-c mice: cellular and humoral activity of long-term regressors.
    Lamon EW; Anderson B; Wigzell H; Fenyö EM; Klein E
    Int J Cancer; 1974 Jan; 13(1):91-104. PubMed ID: 4594340
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibody production and interaction with lymphoid cells in relation to tumor immunity in the Moloney sarcoma virus system.
    Harada M; Pearson G; Redmon L; Winters E; Kasuga S
    J Immunol; 1975 Apr; 114(4):1318-22. PubMed ID: 1090675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of normal lymphocyte cytotoxicity by sera with high antibody titers against H-2 or virus-associated antigens.
    Harada M; Pearson G; Pettigrew H; Redmon L; Orr T
    Cancer Res; 1973 Nov; 33(11):2886-93. PubMed ID: 4583975
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantitative detection of cytotoxic antibodies against tumor-specific antigens of murine sarcomas induced by 3-methylcholanthrene.
    Bloom ET
    J Natl Cancer Inst; 1970 Sep; 45(3):443-53. PubMed ID: 5523193
    [No Abstract]   [Full Text] [Related]  

  • 8. Blocking of syngeneic effector T cells by soluble tumour antigens.
    Plata F; Levy JP
    Nature; 1974 May; 249(454):271-4. PubMed ID: 4545403
    [No Abstract]   [Full Text] [Related]  

  • 9. A microassay for humoral cytotoxicity demonstrating sublethal effects of antibody.
    Cleveland PH; McKhann CF; Johnson K; Nelson S
    Int J Cancer; 1974 Sep; 14(3):417-26. PubMed ID: 4459274
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on purification of antibodies against tumor-specific antigens.
    Park MM
    Pahlavi Med J; 1978 Jan; 9(1):1-26. PubMed ID: 652378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking of cell-mediated immunity to Moloney murine sarcoma virus-transformed cells by lactate dehydrogenase virus-antibody complex.
    McDonald TL
    J Natl Cancer Inst; 1983 Mar; 70(3):493-7. PubMed ID: 6572738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective.
    Livingston PO; DeLeo AB; Jones M; Oettgen HF
    J Immunol; 1983 Nov; 131(5):2601-5. PubMed ID: 6631013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo growth and antigenic properties of a rat sarcoma induced by Moloney sarcoma virus.
    Jones JM; Jensen F; Veit B; Feldman JD
    J Natl Cancer Inst; 1974 Jun; 52(6):1771-7. PubMed ID: 4134500
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on mouse Moloney virus induced tumours: I. The detection of p30 as a cytotoxic target on murine Moloney leukaemic spleen cells, and on an in vitro Moloney sarcoma line by antibody mediated cytotoxicity.
    Epstein LB; Knight RA
    Br J Cancer; 1975 May; 31(5):499-512. PubMed ID: 50852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies to the envelope proteins of Moloney leukemia virus: characterization of recombinant viruses.
    Cicurel L; Lee JC; Enjuanes L; Ihle JN
    Transplant Proc; 1980 Sep; 12(3):394-7. PubMed ID: 7222218
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased tumorigenesis of murine sarcoma virus (Moloney) by coinfection with Rauscher virus or by treatment with antilymphocyte serum.
    Hook WA; Chirigos MA; Chan SP
    Cancer Res; 1969 May; 29(5):1008-12. PubMed ID: 5781092
    [No Abstract]   [Full Text] [Related]  

  • 17. Serologic analysis of tumor-associated surface antigens on a Moloney leukemia virus-induced lymphoma, MBL-2.
    Ng AK; McIntire R; Holden HT; Herberman RB
    J Immunol; 1978 Sep; 121(3):856-62. PubMed ID: 690439
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
    Vallera DA; Mentzer SJ; Maizel SE
    Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of cytotoxic immune lymphoid cells following regression of virus-induced sarcomas in mice.
    Levy JP; Lechlerc JC; Gomard E; Pavie J; Kourilsky F
    Bibl Haematol; 1973; 39():689-97. PubMed ID: 4798253
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunity to tumours of the murine leukaemia-sarcoma virus complex.
    Owen JJ; Seeger RC
    Br J Cancer Suppl; 1973 Aug; 1():26-34. PubMed ID: 4374230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.